Back to top

B. Riley Securities Remains a Buy on Kymera Therapeutics (KYMR)

B. Riley Securities analyst maintained a Buy rating on Kymera Therapeutics today and set a price target of $155.00. Kymera Therapeutics has an anal...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Kymera Therapeutics, Inc. (KYMR)